1. Pizzi LT, Lofland JH. Economic Evaluation in U.S. Health Care: Principles and Applications: 2005: Jones & Bartlett Publishers.

  2. Dalziel K, Segal L, Mortimer D. Review of Australian health economic evaluation - 245 interventions: what can we say about cost effectiveness? Cost Eff Resour Alloc. 2008;6:9.

  3. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis, 2000. 20(1): p. 1-16.

  4. Aceijas C, Stimson GV, Hickman M, Rhodes T. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS, 2004. 18(17): p. 2295-303.

  5. AIDS epidemic update 2007, World Health Organization.

  6. Annual Surveillance Report: HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia. 2007, National Centre in HIV Epidemiology and Clinical Research.

  7. Ball AL, Rana S, Dehne KL. HIV prevention among injecting drug users: responses in developing and transitional countries. Public Health Rep 1998. 113: p. 170-181.

  8. Bruneau J, Lamothe F, Franco E, Lachance N, Desy M, Soto J et al. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. Am J Epidemiol 1997. 146(12): p. 994-1002.

  9. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999. 149(3): p. 203-13.

  10. van Ameijden EJ, van den Hoek JA, Hartgers C, Coutinho RA. Risk factors for the transition from noninjection to injection drug use and accompanying AIDS risk behavior in a cohort of drug users. Am J Epidemiol 1994. 139: p. 1153-1163.

  11. Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet 1997. 349(9068): p. 1797-800.

  12. Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse, 2006. 41: p. 777-813.

  13. Bastos FI, Strathdee SA. Evaluating effectiveness of syringe exchange programmes: current issues and future prospects. Soc Sci Med 2000. 51(12): p. 1771-82.

  14. Vlahov D, Junge B. The role of needle exchange programs in HIV prevention. Public Health Rep 1998. 113 Suppl 1: p. 75-80.

  15. Heimer R. Syringe exchange programs: lowering the transmission of syringe-borne diseases and beyond. Public Health Rep 1998. 113 Suppl 1: p. 67-74.

  16. Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 2001. 15: p. 1329-1341. Top of page

  17. Kidorf M, King VL. Expanding the public health benefits of syringe exchange programs. Can J Psychiatry 2008. 53(8): p. 487-95.

  18. Des Jarlais C, Perlis T, Friedman SR, Chapman T, Kwok J, Rockwell R et al. Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990-1997. Am J Public Health 2000. 90(7): p. 1112-6.

  19. Donoghoe MC, Stimson GV, Dolan K, Alldritt L. Changes in HIV risk behaviour in clients of syringe-exchange schemes in England and Scotland. AIDS 1989. 3(5): p. 267-72.

  20. Wodak A, Dolan K, Imrie AA, Gold J, Wolk J, Whyte BM et al. Antibodies to the human immunodeficiency virus in needles and syringes used by intravenous drug abusers. Med J Aust 1987. 147(6): p. 275-6.

  21. Feachem RGA. Valuing the past... Investing in the future. Evaluation of the National HIV/AIDS Strategy 1993-94 to 1995-96. AGPS, Canberra. 1995.

  22. Needle and syringe programs: position paper. 2002: Australian National Council on Drugs.

  23. Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend 2007. 91(2-3): p. 228-35.

  24. Return on Investment in Needle and Syringe Programs in Australia Report. 2002, Commonwealth Department of Health and Ageing, Health Outcomes International Pty Ltd, National Centre in HIV Epidemiology and Clinical Research: Sydney, Australia.

  25. Jones L, Pickering L, Sumnall H, McVeigh J, Bellis MA. A review of the effectiveness and cost-effectiveness of needle and syringe programmes for injecting drug users. 2006, Centre for Public Health, Liverpool, John Moores University: Liverpool, UK.

  26. Cohen DA, Wu SY, Farley TA. Structural interventions to prevent HIV/sexually transmitted disease: Are they cost-effective for women in the Southern United States? Sexually Transmitted Diseases 2006. 33(7 SUPPL.).

  27. Cohen DA, Wu SY, Farley TA. Comparing the cost-effectiveness of HIV prevention interventions. J Acquir Immune Defic Syndr 2004. 37(3): p. 1404-14.

  28. Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998. 18(SUPPL.): p. S133- S138.

  29. Drucker E, Lurie P, Wodak A, Alcabes P. Measuring harm reduction: the effects of needle and syringe exchange programs and methadone maintenance on the ecology of HIV. AIDS 1998. 12 Suppl A: p. S217-30.

  30. Vickerman P, Miners A, Williams A. Assessing the cost-effectiveness of interventions linked to needle and syringe programmes for injecting drug users: An economic modelling report. 2008, Department of Public Health and Policy, London School of Hygiene and Tropical Medicine: London.Top of page

  31. Cabases JM, Sanchez E. Costs and effectiveness of a syringe distribution and needle exchange program for HIV prevention in a regional setting. European Journal of Health Economics 2003. 4(3): p. 203-208.

  32. Gold M, Gafni A, Nelligan P, Millson P. Needle exchange programs: an economic evaluation of a local experience. Cmaj, 1997. 157(3): p. 255-62.

  33. Jacobs P, Calder P, Taylor M, Houston S, Saunders LD, Albert T. Cost effectiveness of Streetworks' needle exchange program of Edmonton. Can J Public Health 1999. 90(3): p. 168- 71.

  34. Kumaranayake L, Vickerman P, Walker D, Samoshkin S, Romantzov C, Emelyanova Z et al. The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus. Addiction 2004. 99(12): p. 1565-76.

  35. Laufer FN. Cost-effectiveness of syringe exchange as an HIV prevention strategy. J Acquir Immune Defic Syndr 2001. 28(3): p. 273-278.

  36. Harris ZK. Efficient allocation of resources to prevent HIV infection among injection drug users: the Prevention Point Philadelphia (PPP) needle exchange program. Health Econ 2006. 15(2): p. 147-58.

  37. Pinkerton SD, Holtgrave DR, DiFranceisco W, Semaan S, Coyle SL, Johnson-Masotti AP. Cost-threshold analyses of the National AIDS Demonstration Research HIV prevention interventions. AIDS 2000. 14(9): p. 1257-68.

  38. Vickerman P, Kumaranayake L, Balakireva O, Guinness L, Artyukh O, Semikop T et al. The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine. Sex Transm Dis 2006. 33(10 Suppl): p. S89-102.

  39. Pollack HA. Cost-effectiveness of harm reduction in preventing hepatitis C among injection drug users. Med Decis Making 2001. 21(5): p. 357-67.

  40. Hoare A, Regan DG, Wilson DP. Sampling and sensitivity analyses tools (SaSAT) for computational modelling. Theor Biol Med Model 2008. 5: p. 4.

  41. Hepatitis C Virus Projections Working Group: Estimates and Projections of the Hepatitis C Epidemic in Australia. 2006, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales: Sydney, Australia.

  42. Medicare Australia. MBS online. 2008 24 October 2008]; Available from: Medicare Benefits Schedule website.

  43. Department of Health and Ageing. Pharmaceutical Benefits Schedule. 2008 24 october 2008].

  44. Department of Health and Ageing. National Admitted Patient Care Collection (NAPCC) 2004-05. Clinical Profiles 2004-05. 2005 24 Nov 2008];

  45. Department of Health and Ageing. Round 11 (2006-07) Cost Report - Public version 5.1,. 2007;Top of page

  46. Carole A. Federico, Priscilla C. Vuong, Mel Krajden, Eric M et al. Patient Time Costs and Out-of-Pocket Costs in Hepatitis C. Vancouver, British Columbia, Canada: British Columbia Centre for Disease Control. 2009.

  47. Bowie RD, Tobias MI, Williams T. The private costs of HIV/AIDS. N Z Med J 1996. 109: p. 51-54.

  48. Organisation for Economic Cooperation and Development. Purchasing Power Parity. 2008. Available from: Organisation for economic co-operation and development website (Accessed 20 February, 2009).

  49. Dwyer R, Power R, Topp L, Maher L, Conroy A, Jauncey M et al. IRID report:An exploratory study of non-viral injecting-related injuries and diseases among Australian injecting drug users. 2007, Centre for Epidemiology and Population Health Research, Burnet Institute: Melbourne.

  50. Dwyer R, Topp L, Maher L, Power R, Hellard M, Walsh N et al. Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users. Drug Alcohol Depend 2009. 100(1-2): p. 9-16.

  51. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of Health Care Programs. 2005, Oxford: Oxford University Press.

  52. Department of Human Services, Victorian Burden of Disease Study. 2001, Department of Human Services, Melbourne.

  53. Guy R, Devadason D, Lim M, Higgins N, Pedrana A, Gibson K et al. Enhanced case detection for newly acquired hepatitis C infection: epidemiological findings and health service implications. Commun Dis Intell., 2008. 32: p. 250-256.

  54. Iversen J, Topp L, Maher L. Australian NSP Survey National Data Report 2002--2006, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 2007.

  55. Islam M, Wodak A, Conigrave KM. The effectiveness and safety of syringe vending machines as a component of needle syringe programmes in community settings. Int J Drug Policy 2008. 19: p. 436-441.

  56. O'Brien S, Black E, Degenhardt L, Roxburgh A, Campbell G, de Graaff B et al. Australian Drug Trends 2006: Findings from the Illicit Drug Reporting System (IDRS). 2006, Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales.

  57. Topp L, Darke S, Bruno R, Fry C, Hargreaves K, Humeniuk R et al. Australian Drug Trends 2000: Findings of the Illicit Drug Reporting System (IDRS). 2000, Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales.

  58. Topp L, Kaye S, Bruno R, Longo M, Williams P, O'Reilly B et al. Australian Drug Trends 2001: Findings of the Illicit Drug Reporting System (IDRS). 2001, Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales.

  59. Breen C, Degenhardt L, Roxburgh A, Bruno R, Duquemin A, Fetherston J et al. Australian Drug Trends 2002: Findings from the Illicit Drug Reporting System (IDRS). 2002, Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales.Top of page

  60. Breen C, Degenhardt L, Roxburgh A, Bruno R, Fetherston J, Jenkinson R et al. Australian Drug Trends 2003: Findings from the Illicit Drug Reporting System (IDRS). 2003, Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales.

  61. Stafford J, Degenhardt L, Black E, Bruno R, Buckingham K, Fetherston J et al. Australian Drug Trends 2004: Findings from the Illicit Drug Reporting System (IDRS). 2004, Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales.

  62. Stafford J, Degenhardt L, Black E, Bruno R, Buckingham K, Fetherston J et al. Australian Drug Trends 2005: Findings from the Illicit Drug Reporting System (IDRS). 2005, Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales.

  63. Kwon JA, Iversen J, Maher L, Law M, Wilson DP. The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis. J Acquir Immune Defic Syndr 2009. In press.

  64. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. 1991, NY: Oxford University Press.

  65. Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, Kaldor JM et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006. 101(10): p. 1499-508.

  66. 2007 National Drug Strategy Household Survey: first results. 2008, Australian Institute of Health and Welfare: Canberra.

  67. Falster K, Kaldor JM, Maher L. Hepatitis C Virus Acquisition among Injecting Drug Users: A Cohort Analysis of a National Repeated Cross-sectional Survey of Needle and Syringe Program Attendees in Australia, 1995–2004. Journal of Urban Health, 2009. In press.

  68. Hagan H, Pouget ER, Des Jarlais DC, Lelutia-Weinberger C. Meta-Regression of Hepatitis C Virus Infection in Relation to Time Since Onset of Illicit Drug Injection: The Influence of Time and Place. Am J Epidemiol 2008. 168: p. 1099-1109.

  69. Donoghoe MC, Dolan KA, Stimson GV. Life-style factors and social circumstances of syringe sharing in injecting drug users. Br J Addict 1992. 87(7): p. 993-1003.

  70. McKeganey N, Abel M, Taylor A, Frischer M, Goldberg D, Green S. The preparedness to share injecting equipment: an analysis using vignettes. Addiction 1995. 90(9): p. 1253-60.

  71. de Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med 1994. 331(6): p. 341-6.

  72. Padian NS, Shiboski SC, Glass SO, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am J Epidemiol 1997. 146(4): p. 350-7.

  73. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999. 150(3): p. 306-11. Top of page

  74. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1- discordant couples in Rakai, Uganda. Lancet 2001. 357(9263): p. 1149-53.

  75. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O et al. Rates of HIV-1 Transmission per Coital Act, by Stage of HIV-1 Infection, in Rakai, Uganda. J Infect Dis 2005. 191(9): p. 1403-9.

  76. Koblin BA, Husnik MJ, Colfax G, Huang Y, Madison M, Mayer K et al. Risk factors for HIV infection among men who have sex with men. AIDS 2006. 20(5): p. 731-9.

  77. Read TRH, Hocking J, Sinnott V, Hellard M. Risk factors for incident HIV infection in men having sex with men: a case-control study. Sexual Health 2007. 4: p. 35-39.

  78. Grierson J, Thorpe R, Pitts M. HIV Futures 5: Life as we know it, monograph series number 60. 2006, The Australian Research Centre in Sex, Health and Society, Latrobe University, Melbourne, Australia.

  79. Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Family Planning Perspectives 1999. 31: p. 272-279.

  80. Weller SC, Davis KR. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002. (1): p. CD003255.

  81. Pinkerton SD, Abtramson PR. Effectiveness of condoms in preventing HIV transmission. Social Science and Medicine 1997. 44: p. 1303-1312.

  82. Weller SC. A meta-analysis of condom effectiveness in reducing sexually transmitted HIV. Social Science and Medicine 1993. 36(12): p. 1653-44.

  83. Fitch TJ, Stine C, Hagar DW, Mann J, Adam MB, McIlhaney J. Condom Effectiveness: Factors that influence risk reduction. Sexually Transmitted Diseases 2002. 29: p. 811-817.

  84. Alary M, Joly JR, Vincelette J, Lavoie R, Turmel B, Remis RS. Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men. Am J Public Health 2005. 95: p. 502-505.

  85. Tahan V, Karaca C, Yildirim B, Bozbas A, Ozaras R, Demir K et al. Sexual transmission of HCV between spouses. Am J Gastroenterol 2005. 100: p. 821-824.

  86. Terrault NA. Sexual activity as a risk factor for hepatitis C Hepatology, 2002. 36: p. S99- S105.

  87. Australian Bureau of Statistics (3301.0 - Births, Australia, 2007) Australian Bureau of Statistics website (accessed 31 May, 2009).

  88. Recent Increases in Australia's Fertility. 4102.0 - Australian Social Trends, 2007. (Accessed 31 May, 2009). 2009, Australian Bureau of Statistics.

  89. Kind C, Rudin C, Siegrist CA, Wyler CA, Biedermann K, Lauper U et al. Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. Swiss Neonatal HIV Study Group. AIDS, 1998. 12(2): p. 205-10. Top of page

  90. Cooper ER, Nugent RP, Diaz C, Pitt J, Hanson C, Kalish LA et al. After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Transmission Study Group. J Infect Dis 1996. 174(6): p. 1207-11.

  91. Fiscus SA, Adimora AA, Schoenbach VJ, Lim W, McKinney R, Rupar D et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA 1996. 275(19): p. 1483-8.

  92. Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, Wang L et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998. 339(20): p. 1409-14.

  93. Baldo V, Baldovin T, Trivello R, Floreani A. Epidemiology of HCV infection. Curr Pharm Des, 2008. 14: p. 1646-1654.

  94. Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology 2002. 36: p. S106-S113.

  95. Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005. 192: p. 1880-1889.

  96. Blower SM, Dowlatabadi H. Sensitivity and uncertainty analysis of complex-models of disease transmission - an HIV model, as an example. International Statistical Review 1994. 62(2): p. 229-243.

  97. Iman RL, Helton JC, Campbell JE. An Approach To Sensitivity Analysis Of Computer- Models .1. Introduction, Input Variable Selection And Preliminary Variable Assessment. Journal Of Quality Technology 1981. 13(3): p. 174.

  98. Iman RL, Helton JC, Campbell JE. An approach to sensitivity analysis of computer-models .2. Ranking of input variables, response-surface validation, distribution effect and technique synopsis. Journal of Quality Technology 1981. 13(4): p. 232.

  99. Iman RL, Helton JC. An Investigation of Uncertainty and Sensitivity Analysis Techniques for Computer Models. Risk Analysis 1988. 8(1): p. 71-90.

  100. McKay MD, Conover WJ, Beckman RJ. A Comparison of Three Methods for Selecting Values of Input Variables in the Analysis of Output from a Computer Code. Technometrics 1979. 21: p. 239-245.

  101. Stein M. Large sample properties of simulations using Latin Hypercube Sampling. Technometrics 1987. 29: p. 143-151.

  102. Handcock MS. Latin Hypercube Sampling to Improve the Efficiency of Monte Carlo Simulations: Theory and Implementation in ASTAP. IBM Research Division, TJ Watson Research Center, RC 14546. 1989. Top of page

  103. Fedra K, Van Straten G, Beck MB. Uncertainty and arbitrariness in ecosystems modeling: A lake modeling example. Ecological Modelling 1981. 13: p. 87-110.

  104. Rose KA, Smith EP, Gardner RH, Brenkert AL, Bartell SM. Parameter sensitivities, monte carlo filtering, and model forecasting under uncertainty. Journal of Forecasting 1991. 10: p. 117-133.

  105. Saltelli A. Sensitivity Analysis for Importance Assessment. Risk Analysis 2002. 22(3): p. 579-590.

  106. Rosner B. Fundamentals of Biostatistics (6th Ed.). 2006, Duxbury Press: Boston. p. 538-543.

  107. Iman RL, Conover WJ. Small Sample Sensitivity Analysis Techniques for Computer-Models, With An Application To Risk Assessment. Communications In Statistics Part A-Theory And Methods 1980. 9(17): p. 1749.

  108. Iman RL, Helton JC. An Investigation Of Uncertainty And Sensitivity Analysis Techniques For Computer-Models. Risk Analysis 1988. 8(1): p. 71.

  109. McKay MD, Beckman RJ, Conover WJ. A comparison of three methods for selecting values of input variables in the analysis of output from a computer code. Technometrics 2000. 42(1): p. 55.

  110. Blower SM, Hartel D, Dowlatabadi H, Anderson RM, May RM. Drugs, sex and HIV: a mathematical model for New York City. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences, 1991. 331(1260): p. 171-87.

  111. Blower SM, McLean AR, Porco TC, Small PM, Hopewell PC, Sanchez MA et al. The intrinsic transmission dynamics of tuberculosis epidemics. Nat Med 1995. 1(8): p. 815-21.

  112. Porco TC, Blower SM. Quantifying the intrinsic transmission dynamics of tuberculosis. Theoretical Population Biology 1998. 54(2): p. 117-32.

  113. Sanchez MA, Blower SM. Uncertainty and sensitivity analysis of the basic reproductive rate. Tuberculosis as an example. Am J Epidemiol 1997. 145(12): p. 1127-37.

  114. Blower S, Ma L. Calculating the contribution of herpes simplex virus type 2 epidemics to increasing HIV incidence: treatment implications. Clin Infect Dis 2004. 39 Suppl 5: p. S240- 7.

  115. Blower S, Ma L, Farmer P, Koenig S. Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance. Current Drug Targets: Infectious Disorders, 2003. 3(4): p. 345-53.

  116. Blower SM, Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med 2004. 10(10): p. 1111-6.

  117. Breban R, McGowan I, Topaz C, Schwartz EJ, Anton P, Blower S. Modeling the potential impact of rectal microbicides to reduce HIV transmission in bathhouses. Mathematical Biosciences and Engineering 2006. 3(3): p. 459-466. Top of page

  118. Schroeder LD, Sqoquist DL, Stephan PE. Understanding regression analysis. 1986, Sage Publications. p. 31-32.

  119. Saltelli A, Tarantola S. On the relative importance of input factors in mathematical models: Safety assessment for nuclear waste disposal. J Am Stat Assoc 2002. 97(459): p. 702-709.

  120. Turanyi T, Rabitz H. Local methods and their applications, in Sensitivity Analysis, Saltelli A, Chan K, Scott M Editors. 2000, John Wiley: New York.

  121. Varma A, Morbidelli M, Wu H. Parametric Sensitivity in Chemical Systems. 1999, Cambridge: Cambridge Series in Chemical Engineering.

  122. Goldsmith CH. Sensitivity Analysis, in Encyclopedia of Biostatistics, Armitage P, Colton T Editors. 1998, John Wiley.

  123. Campolongo F, Saltelli A, Jensen NR, Wilson J, Hjorth J. The Role of Multiphase Chemistry in the Oxidation of Dimethylsulphide (DMS). A Latitude Dependent Analysis. J Atmospheric Chemistry 1999. 32: p. 327-356.

  124. Campolongo F, Tarantola S, Saltelli A. Tackling quantitatively large dimensionality problems. Computer Physics Communications 1999. 117: p. 75-85.

  125. Kioutsioukis I, Tarantola S, Saltelli A, Gatelli D. Uncertainty and global sensitivity analysis of road transport emission estimates. Atmospheric Environment 2004. 38: p. 6609-6620.

  126. Crosetto M, Tarantola S. Uncertainty and sensitivity analysis: tools for GIS-based model implementation. International Journal of Geographic Information Science 2001. 15(4): p. 415- 437.

  127. Pastorelli R, Tarantola S, Beghi MG, Bottani CE, Saltelli A. Design of surface Brillouin scattering experiments by sensitivity analysis Surface Science 2000. 468: p. 37-50.

  128. Rabitz H. Efficient input-output model representations. Computer Physics Communications 1999. 117: p. 11-20.

  129. Rabitz H, Ali OF. Managing the tyranny of parameters in mathematical modelling of physical systems, in Sensitivity Analysis, Saltelli A, Chan K, Scott M Editors. 2000, John Wiley: New York. p. 385-397.

  130. Archer G, Saltelli A, Sobol IM. Sensitivity measures, ANOVA like techniques and the use of bootstrap. J Statistical Computation and Simulation 1997. 58: p. 99-120.

  131. Hoare A, Regan DG, Wilson DP. Sampling and Sensitivity Analyses Tools (SaSAT) for Computational Models. Theor Biol Med Model 2008. 5:4.

  132. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008. 372(9651): p. 1733-45.

  133. Stoove MA, Dietze PM, Aitken CK, Jolley D. Mortality among injecting drug users in Melbourne: a 16-year follow-up of the Victorian Injecting Cohort Study (VICS). Drug Alcohol Depend 2008. 96(3): p. 281-5.Top of page

  134. Abdala N, Gleghorn AA, Carney JM, Heimer R. Can HIV-1-Contaminated Syringes Be Disinfected? Implications for Transmission Among Injection Drug Users. J Acq Imm Defic Syndr 2001. 28(5): p. 487-494.

  135. Siegel J, Weinstein M, Fineberg H. Bleach programs for preventing AIDS among IV drug users: modeling the impact of HIV prevalence. Am J Public Health 1991. 81(10): p. 1273- 1279.

  136. Abdala N, Crowe M, Tolstov Y, Heimer R. Survival of human immunodeficiency virus type 1 after rinsing injection syringes with different cleaning solutions. Subst Use Misuse 2004. 39(4): p. 581-600.

  137. Hagan H, Thiede H. Does bleach disinfection of syringes help prevent hepatitis C virus transmission. Epidemiology 2003. 14(5): p. 628-629.

  138. Agolini G, Russo A, Clementi M. Effect of phenolic and chlorine disinfectants on hepatitis C virus binding and infectivity. Am J Infect Control 1999. 27(3): p. 236-9.

  139. Kapadia F, Vlahov D, Des Jarlais DC, Strathdee SA, Ouellet L, Kerndt P et al. Does Bleach Disinfection of Syringes Protect Against Hepatitis C Infection Among Young Adult Injection Drug Users? Epidemiology 2002; 13(6): p. 738.

  140. Syringe disinfection for Injection Drug Users 2007, Centers for Disease Control and Prevention

  141. Crofts N, Aitken CK, Kaldor JM. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Aust 1999;170:220-1.

  142. Law MG, Dore GJ, Bath N, Thompson S, Crofts N, Dolan K et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol 2003. 32(5): p. 717-24.

  143. Degenhardt L, Rendle V, Hall W, Gilmour S, Law W. Estimating the number of current regular heroin users in New South Wales and Australia 1997-2002. NDARC Technical Report No. 198 2004, Sydney: National Drug and Alcohol Research Centre.

  144. Australian Institute of Health and Welfare, 2007 National Drug Strategy Household Survey: first results. 2008, Canberra: AIHW.

  145. Australian demographic statistics. June 2008 Australian Bureau of Statistics (ABS).

  146. MacDonald M, Zhou J. Australian NSP Survey National Data report 1995-2001. June 2002, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales.

  147. Australian Institute of Health and Welfare 2007, Statistics on drug use in Australia 2006. Drug Statistics Series No. 18. Cat. no. PHE 80. , Canberra: AIHW.

  148. Australian Institute of Health and Welfare 2008, National Opioid Pharmacotherapy Statistical Annual Data (NOPSAD) Collection Data Guide: Data Items and Definitions 2007, IHW Working Paper. Cat. no. WP 60.Canberra: AIHW. Top of page

  149. Australian Crime Commission (ACC) Australian illicit drug reports and Illicit drug data reports, 1996–2007.

  150. Australian demographic statistics. December 2002, Australian Bureau of Statistics (ABS).

  151. Smith C, d'Arminio Monforte A, de Wit S, Friis-Moller N, Lundgren J, Philips Andrew et al. Causes of death in the D:A:D study-initial results. 2008.

  152. Degenhardt L, Rendle V, Hall W, Gilmour S, Law W. Mortality among dependent users of heroin and other opioids: Illicit Drugs Discussion Paper No. 9. 2008, National Drug and Alcohol Research Centre, University of New South Wales: Sydney.

  153. Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O'Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction 2008. 103(3): p. 462-8.

  154. Gibson AE, Degenhardt LJ. Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. Drug Alcohol Rev 2007. 26(4): p. 405-10.

  155. Baggaley RF, Boily MC, White RG, Alary M. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS 2006. 20(6): p. 805-12.

  156. Hudgens MG, Longini IM, Jr, Vanichseni S, Hu DJ, Kitayaporn D, Mock PA et al. Subtypespecific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand. Am J Epidemiol 2002. 155(2): p. 159-68.

  157. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997. 126(12): p. 946-54.

  158. Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004. 364(9428): p. 51-62.

  159. Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007. 370(9585): p. 407-13.

  160. Smith CJ, Phillips AN, Hill T, Fisher M, Gazzard B, Porter K et al. The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: Results from a multicenter cohort study. J Infect Dis 2005. 192(8): p. 1387-1397.

  161. Henderson DK, Fahey BJ, Willy M, Schmitt JM, Carey K, Koziol DE et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation. Ann Intern Med 1990. 113(10): p. 740-6.

  162. Cavalcante NJ, Abreu ES, Fernandes ME, Richtmann R, Piovesana MN, Yamada FT et al. Risk of health care professionals acquiring HIV infection in Latin America. AIDS Care 1991. 3(3): p. 311-6. Top of page

  163. Gerberding JL. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: final report from a longitudinal study. J Infect Dis 1994. 170(6): p. 1410-7.

  164. Ippolito G, Puro V, De Carli G. The risk of occupational human immunodeficiency virus infection in health care workers. Italian Multicenter Study. The Italian Study Group on Occupational Risk of HIV infection. Arch Intern Med 1993. 153(12): p. 1451-8.

  165. Nelsing S, Nielsen TL, Nielsen JO. Occupational exposure to human immunodeficiency virus among health care workers in a Danish hospital. J Infect Dis 1994. 169(2): p. 478.

  166. Tokars JI, Marcus R, Culver DH, Schable CA, McKibben PS, Bandea CI et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. The CDC Cooperative Needlestick Surveillance Group. Ann Intern Med 1993. 118(12): p. 913-9.

  167. Patz JA, Jodrey D. Occupational health in surgery: risks extend beyond the operating room. Aust N Z J Surg 1995. 65(9): p. 627-9.

  168. Kaplan EH, O'Keefe E. Let the needles do the talking! Evaluating the New Haven needle exchange. Interfaces 1993. 23(1): p. 7-26.

  169. Peters L, Mocroft A, Soriano V, Rockstroh J, Jurgen K, Losso M et al. Hepatitis C Virus Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1-Infected Patients With Maximum Virologic Suppression. J Acq Imm Defic Syndr 50(5)(April 2009): p. 457-463.

  170. Lodwick RK, Smith CJ, Youle M, Lampe FC, Tyrer M, Bhagani S et al. Stability of antiretroviral regimens in patients with viral suppression. AIDS 2008. 22(9): p. 1039-46.

  171. Short LJ, Bell Dm. Risk of occupational infection with blood-borne pathogens in operating and delivery room settings. Am J Infect Control 1993. 21(6): p. 343-50.

  172. Gerberding JL. Management of Occupational Exposures to Blood-Borne Viruses. N Engl J Med 1995. 332(7): p. 444.

  173. MacDonald M, Crofts N, Kaldor J. Transmission of hepatitis C virus: rates, routes, and cofactors. Epidemiol Rev 1996. 18(2): p. 137-48.

  174. Kiyosawa K, Sodeyama T, Tanaka E, Nakano Y, Furuta S, Nishioka K et al. Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med 1991. 115(5): p. 367-9.

  175. Sodeyama T, Kiyosawa K, Urushihara A, Matsumoto A, Tanaka E, Furuta S et al. Detection of hepatitis C virus markers and hepatitis C virus genomic-RNA after needlestick accidents. Arch Intern Med 1993. 153(13): p. 1565-72.

  176. Hamid SS, Farooqui B, Rizvi Q, Sultana T, Siddiqui AA. Risk of transmission and features of hepatitis C after needlestick injuries. Infect Control Hosp Epidemiol 1999. 20(1): p. 63-4.

  177. De Carli G, Puro V, Ippolito G. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. Infection 2003. 31 Suppl 2: p. 22-7.

  178. Santantonio T, Medda E, Ferrari C, Fabris P, Cariti G, Massari M et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis 2006. 43(9): p. 1154-9.Top of page

  179. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003. 37(1): p. 60-4.

  180. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Hepatology 2008. 48(2): p. 418-431.

  181. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIVinfected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008. 22(15): p. 1979-91.

  182. Bruno R, Sacchi P, Puoti M, Maiocchi L, Patruno S, Carosi G et al. Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. J Acq Imm Defic Syndr 2007. 46(3): p. 297-303.

  183. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997. 25(3): p. 754-8.

  184. Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999. 85(10): p. 2132-7.

  185. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000. 47(1): p. 131-6.

  186. del Olmo JA, Serra MA, Rodriguez F, Escudero A, Gilabert S, Rodrigo JM. Incidence and risk factors for hepatocellular carcinoma in 967 patients with cirrhosis. J Cancer Res Clin Oncol 1998. 124(10): p. 560-4.

  187. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997. 112(2): p. 463-72.

  188. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002. 97(11): p. 2886-95.

  189. Gentilini P, Laffi G, La Villa G, Romanelli RG, Buzzelli G, Casini-Raggi V et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol 1997. 92(1): p. 66-72.

  190. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virusrelated cirrhosis and history of parenteral exposure in the United States. Hepatology 1999. 29(4): p. 1311-6.

  191. Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology 2005. 42(3): p. 711-23. Top of page

  192. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993. 18(1): p. 47-53.

  193. Imberti D, Fornari F, Sbolli G, Buscarini E, Squassante L, Buscarini L. Hepatocellular carcinoma in liver cirrhosis. A prospective study. Scand J Gastroenterol 1993. 28(6): p. 540- 4.

  194. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hürter D et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998. 28(6): p. 1687-95.

  195. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995. 346(8982): p. 1051-5.

  196. Serfaty L, Aumaître H, Chazouillères O, Bonnand AM, Rosmorduc O, Poupon RE et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998. 27(5): p. 1435-40.

  197. Tsai JF, Jeng JE, Ho MS, Chang WY, Hsieh MY, Lin ZY et al. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 1997. 76(7): p. 968-74.

  198. Planas R, Ballesté B, Alvarez MA, Rivera M, Montoliu S, Galeras JA et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004. 40(5): p. 823-30.

  199. Sweeting MJ, De Angelis D, Brant LJ, Harris HE, Mann AG, Ramsay ME. The burden of hepatitis C in England. J Viral Hepat 2007. 14(8): p. 570-6.

  200. Krahn M, Wong JB, Heathcote J, Scully L, Seeff L. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Making 2004. 24(1): p. 20-9.

  201. Annual Surveillance Report: HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia. 2008, National Centre in HIV Epidemiology and Clinical Research.

  202. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998. 28(3): p. 823-30.

  203. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT et al. Longterm outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996. 334(13): p. 815-20.

  204. Hepatitis C Virus Projections Working Group : Estimates and projections of the Hepatitis C virus epidemic in Australia 2006. National Centre in HIV Epidemiology and Clinical Research. Top of page

  205. Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol 2008. 103(5): p. 1283-97.

  206. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002. 347(13): p. 975-82.

  207. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001. 358(9286): p. 958-65.

  208. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004. 351(5): p. 438-50.

  209. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006. 13(1): p. 34-41.

  210. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008. 198(9): p. 1337-44.

  211. Piasecki BA, Lewis JD, Reddy KR, Bellamy SL, Porter SB, Weinrieb RM et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology 2004. 40(4): p. 892-9.

  212. Grebely J, Raffa JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol 2007. 21(7): p. 447-51.

  213. Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006. 43(5): p. 923-31.

  214. Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006. 130(3): p. 632-8.

  215. Broers B, Helbling B, François A, Schmid P, Chuard C, Hadengue A et al. Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005. 42(3): p. 323-8.

  216. De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Calleri G et al. Twelveweek treatment of acute hepatitis C virus with pegylated interferon- alpha -2b in injection drug users. Clin Infect Dis 2007. 45(5): p. 583-8.

  217. De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Raiteri R et al. Dosedependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C. J Antimicrob Chemother 2006. 57(2): p. 360-3. Top of page

  218. Dominguez S, Ghosn J, Valantin MA, Schruniger A, Simon A, Bonnard P et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIVinfected patients. AIDS 2006. 20(8): p. 1157-61.

  219. Vogel M, Bieniek B, Jessen H, Schewe CK, Hoffmann C, Baumgarten A et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat 2005. 12(2): p. 207-11.

  220. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med, 2004. 140(5): p. 346-55.

  221. Krawitt EL, Gordon SR, Grace ND, Ashikaga T, Ray MA, Palmer M et al. A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2006. 101(6): p. 1268-73.

  222. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004. 292(23): p. 2839-48.

  223. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIVcoinfected persons. N Engl J Med 2004. 351(5): p. 451-9.

  224. Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004. 18(13): p. F27-36

  225. Crespo M, Sauleda S, Esteban JI, Juarez A, Ribera E, Andreu AL et al. Peginterferon alpha- 2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIVcoinfected patients. J Viral Hepat 2007. 14(4): p. 228-38.

  226. Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamedi A, Alashgar H et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004. 24(6): p. 568-74.

  227. Bosques-Padilla F, Trejo-Estrada R, Campollo-Rivas O, Cortez-Hernández C, Dehesa- Violante M, Maldonado-Garza H et al. Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. Ann Hepatol 2003. 2(3): p. 135-9.

  228. Gish RG, Arora S, Rajender Reddy K, Nelson DR, O'Brien C, Xu Y et al. Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol 2007. 47(1): p. 51-9.

  229. Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005. 12(3): p. 283-91.Top of page

  230. Mimidis K, Papadopoulos VP, Elefsiniotis I, Koliouskas D, Ketikoglou I, Paraskevas E et al. Hepatitis C virus survival curve analysis in naive patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data. J Gastrointestin Liver Dis 2006. 15(3): p. 213-9.

  231. Hurley SF, Kaldor JM, Carlin JB, Gardiner S, Evans DB, Chondros P et al. The usage and costs of health services for HIV infection in Australia. AIDS 1995. 9(7): p. 777-85.

  232. Hurley SF, Kaldor JM, Gardiner S, Carlin JB, Assuncao RM, Evans DB. Lifetime cost of human immunodeficiency virus-related health care. J Acquir Immune Defic Syndr Hum Retrovirol 1996. 12(4): p. 371-8.

  233. Grierson J, Thorpe R, Pitts M. HIV FUTURES 5. The state of the positive nation. 2006, ARCSHS: Melbourne.

  234. Garattini L, Tediosi F, Di Cintio E, Yin D, Parazzini F. Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV 2001. 13(6): p. 733-741.

  235. HIV Research Network. Hospital and outpatient health services utilization among HIVinfected patients in care in 1999. J Acquir Immune Defic Syndr 2002. 30(1): p. 21-26.

  236. Chen RY, Accortt NA, Westfall AO, Mugavero MJ, Raper JL, Cloud GA et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006. 42(7): p. 1003-10.

  237. Medicare Statistics. 2008 15 April 2009; Available from: Statistics section of Medicare Australia's website.

  238. Phillips A. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004. 18(1): p. 51-8.

  239. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F et al. Prognosis of HIV-1- infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002. 360(9327): p. 119-29.

  240. Fleishman JA, Gebo KA, Reilly ED, Conviser R, Christopher Mathews W, Todd Korthuis P et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care 2005. 43(9 Suppl): p. III40-52.

  241. Lundgren JD, Mocroft A. The impact of antiretroviral therapy on AIDS and survival. J HIV Ther 2006. 11(2): p. 36-8.

  242. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, Australian Commentary on DHHS Guidelines for the use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2008.

  243. Gold M, Siegel J, Russell L, Weinstein M. Cost effectiveness in Health and Medicine 1996, Oxford University Press, New York.

  244. Mullins CD, Whitelaw G, Cooke JL, Beck EJ. Indirect cost of HIV infection in England. Clin Ther 2000. 22(11): p. 1333-1345.Top of page

  245. Scitovsky AA, Rice DP. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. Public Health Rep 1987. 102(1): p. 5-17.

  246. Sendi P, Schellenberg F, Ungsedhapand C, Kaufmann GR, Bucher HC, Weber R et al. Productivity costs and determinants of productivity in HIV-infected patients. Clin Ther 2004. 26(5): p. 791-800.

  247. Organisation for Economic Cooperation and Development. Purchasing Power Parity 2008 [cited 2008; Available from: Organisation for economic cooperation and development's website.

  248. PBAC, Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). 2008, Australian Department of Health and Ageing: Canberra.

  249. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995. 14(2): p. 171-89.

  250. Canadian Agency for Drugs and Technologies in Health. Guidelines for submissions. 2006.

  251. Sendi P, Brouwer WB, Bucher HC, Weber R, Battegay M. When time is more than money: The allocation of time between work and leisure in HIV-infected patients. Soc Sci Med, 2007. 64(11): p. 2355-61.

  252. Crofts N, Aitken CK. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995. Med J Aust, 1997. 167(1): p. 17-20.

  253. Loxley W, Carruthers SJ, Bevan J. In the same vein: first report of the Australian study of HIV and injecting drug use. 1995, National Centre for Research into the Prevention of Drug Abuse, Curtin University, Perth.

  254. HepCare Project. Report of a hepatitis C participant questionnaire in the Northern Sydney Area Health Service and the Hunter Area Health Service. Preliminary report. 1998.

  255. Australian Bureau of Statistics, National Health Survey - (2004 - 05). , Australian Bureau of Statistics: Canberra.

  256. Australian Bureau of Statistics, Employee earnings, benefits and Trade Union Membership 2003.

  257. Magnus A, Mihalopoulos C, Carter R. Department of Treasury and Finance. Evaluation of Preventive Health Interventions. 2008, Deakin University: Burwood.

  258. J Grierson, R Thorpe and M Pitts. HIV Futures 5: Life as we know it. 2006, monograph series number 60, The Australian Research Centre in Sex, Health and Society, Latrobe University, Melbourne, Australia.

  259. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT et al. Survival of Persons with and without HIV Infection in Denmark, 1995-2005. Ann Intern Med 2007. 146(2): p. 87-95.

  260. Day CA, White B, Thein HH, Doab A, Dore GJ, Bates A et al. Experience of hepatitis C testing among injecting drug users in Sydney, Australia. AIDS Care 2008. 20: p. 116-123.

  261. White B, Day C, Thein HH, Doab A, Bates A, Holden J et al. Acceptability of hepatitis C virus testing methods among injecting drug users. Drug Alcohol Rev 2008: p. 1-5.
Top of page